

Brad H Nelson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4523972/publications.pdf>

Version: 2024-02-01

125
papers

14,347
citations

30070

54
h-index

20961

115
g-index

131
all docs

131
docs citations

131
times ranked

21160
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679. | 28.4 | 839 |
| 2 | Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. <i>Genome Research</i> , 2014, 24, 743-750. | 5.5 | 534 |
| 3 | IL-2, Regulatory T Cells, and Tolerance. <i>Journal of Immunology</i> , 2004, 172, 3983-3988. | 0.8 | 532 |
| 4 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335. | 4.3 | 530 |
| 5 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251. | 4.3 | 469 |
| 6 | CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27 ^{hi} Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3281-3292. | 7.0 | 447 |
| 7 | Biology of the Interleukin-2 Receptor. <i>Advances in Immunology</i> , 1998, 70, 1-81. | 2.2 | 420 |
| 8 | Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. <i>Nature Medicine</i> , 2019, 25, 89-94. | 30.7 | 413 |
| 9 | Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3005-3015. | 7.0 | 402 |
| 10 | The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature. <i>Clinical Cancer Research</i> , 2012, 18, 3022-3029. | 7.0 | 390 |
| 11 | Cancer stemness, intratumoral heterogeneity, and immune response across cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9020-9029. | 7.1 | 372 |
| 12 | Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. <i>Genome Research</i> , 2009, 19, 1817-1824. | 5.5 | 361 |
| 13 | CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes. <i>Journal of Immunology</i> , 2010, 185, 4977-4982. | 0.8 | 360 |
| 14 | Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. <i>PLoS ONE</i> , 2009, 4, e6412. | 2.5 | 354 |
| 15 | Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 434-444. | 7.0 | 340 |
| 16 | Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation. <i>Nature</i> , 1994, 369, 333-336. | 27.8 | 321 |
| 17 | Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R126. | 5.0 | 315 |
| 18 | Oncolytic viruses as engineering platforms for combination immunotherapy. <i>Nature Reviews Cancer</i> , 2018, 18, 419-432. | 28.4 | 288 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 6125-6135. | 7.0 | 287 |
| 20 | PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 293-302. | 1.4 | 261 |
| 21 | Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. <i>Cell</i> , 2018, 173, 1755-1769.e22. | 28.9 | 261 |
| 22 | New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway. <i>Molecular and Cellular Biology</i> , 2000, 20, 7109-7120. | 2.3 | 241 |
| 23 | The IL-2 Receptor Promotes Lymphocyte Proliferation and Induction of the c-myc, bcl-2, and bcl-x Genes Through the trans-Activation Domain of Stat5. <i>Journal of Immunology</i> , 2000, 164, 2533-2541. | 0.8 | 212 |
| 24 | PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 926-935. | 3.4 | 169 |
| 25 | Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1493-1502. | 7.0 | 157 |
| 26 | FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism. <i>Molecular and Cellular Biology</i> , 2004, 24, 10058-10071. | 2.3 | 155 |
| 27 | Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 406-421. | 9.4 | 155 |
| 28 | BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750. | 5.5 | 151 |
| 29 | The impact of T cell immunity on ovarian cancer outcomes. <i>Immunological Reviews</i> , 2008, 222, 101-116. | 6.0 | 144 |
| 30 | A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. <i>Blood</i> , 2011, 118, 4853-4862. | 1.4 | 144 |
| 31 | Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1125-1134. | 7.0 | 144 |
| 32 | Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214. | 4.4 | 139 |
| 33 | CD103 and Intratumoral Immune Response in Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6290-6297. | 7.0 | 125 |
| 34 | Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 925-934. | 7.0 | 125 |
| 35 | Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. <i>PLoS ONE</i> , 2016, 11, e0155189. | 2.5 | 112 |
| 36 | A Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer Initiation. <i>Cancer Research</i> , 2011, 71, 4484-4493. | 0.9 | 110 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. <i>Nature Reviews Cancer</i> , 2022, 22, 414-430. | 28.4 | 109 |
| 38 | Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3001-3006. | 7.1 | 102 |
| 39 | Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 2537-2548. | 7.0 | 101 |
| 40 | Stat5 and Sp1 Regulate Transcription of the Cyclin D2 Gene in Response to IL-2. <i>Journal of Immunology</i> , 2001, 166, 1723-1729. | 0.8 | 93 |
| 41 | Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2012, 10, 33. | 4.4 | 93 |
| 42 | Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. <i>Journal of Pathology</i> , 2013, 229, 515-524. | 4.5 | 88 |
| 43 | Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. <i>Oncolmmunology</i> , 2018, 7, e1502905. | 4.6 | 80 |
| 44 | Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580. | 7.0 | 79 |
| 45 | Transcription-induced Chromatin Remodeling at the c-myc Gene Involves the Local Exchange of Histone H2A.Z. <i>Journal of Biological Chemistry</i> , 2005, 280, 25298-25303. | 3.4 | 78 |
| 46 | Tumor-infiltrating B cells and T cells. <i>Oncolmmunology</i> , 2012, 1, 1623-1625. | 4.6 | 77 |
| 47 | Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian Cancer. <i>PLoS ONE</i> , 2008, 3, e2633. | 2.5 | 74 |
| 48 | Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. <i>Cell Reports</i> , 2019, 29, 2338-2354.e7. | 6.4 | 74 |
| 49 | Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. <i>BMC Cancer</i> , 2018, 18, 347. | 2.6 | 67 |
| 50 | Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. <i>International Journal of Cancer</i> , 2003, 104, 73-84. | 5.1 | 65 |
| 51 | Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2092-2105. | 1.8 | 64 |
| 52 | Oncolytic vesicular stomatitis virus expressing interferon- β has enhanced therapeutic activity. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16001. | 4.4 | 63 |
| 53 | Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 ($\hat{1}\pm E/\hat{1}^27$) Tj ETQq1 1 0.784314 rgBT /Over 1.4 59 | | |
| 54 | A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2010, 16, 4046-4056. | 7.0 | 53 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Location, location, location. <i>Oncolmmunology</i> , 2014, 3, e27668. | 4.6 | 53 |
| 56 | B cells and cancer. <i>Cancer Cell</i> , 2021, 39, 1293-1296. | 16.8 | 52 |
| 57 | Phosphatidylinositol 3-Kinase Potentiates, but Does Not Trigger, T Cell Proliferation Mediated by the IL-2 Receptor. <i>Journal of Immunology</i> , 2001, 167, 2714-2723. | 0.8 | 51 |
| 58 | A Permissive Role for Phosphatidylinositol 3-Kinase in the Stat5- mediated Expression of Cyclin D2 by the Interleukin-2 Receptor. <i>Journal of Biological Chemistry</i> , 2004, 279, 5520-5527. | 3.4 | 51 |
| 59 | ESRRA-C11orf20 Is a Recurrent Gene Fusion in Serous Ovarian Carcinoma. <i>PLoS Biology</i> , 2011, 9, e1001156. | 5.6 | 50 |
| 60 | STAT5 Is Essential for Akt/p70S6 Kinase Activity during IL-2-Induced Lymphocyte Proliferation. <i>Journal of Immunology</i> , 2007, 179, 5301-5308. | 0.8 | 49 |
| 61 | Interleukin-2 Signaling and the Maintenance of Self-Tolerance. , 2001, 5, 92-112. | | 46 |
| 62 | Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4089-4100. | 7.0 | 46 |
| 63 | 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. <i>Science Advances</i> , 2021, 7, . | 10.3 | 46 |
| 64 | Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. <i>Clinical Chemistry</i> , 2016, 62, 1238-1247. | 3.2 | 45 |
| 65 | Profiling model T-cell metagenomes with short reads. <i>Bioinformatics</i> , 2009, 25, 458-464. | 4.1 | 43 |
| 66 | Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers. <i>PLoS ONE</i> , 2007, 2, e1281. | 2.5 | 42 |
| 67 | Tumour immunotherapy: lessons from predatorâ€“prey theory. <i>Nature Reviews Immunology</i> , 2022, 22, 765-775. | 22.7 | 41 |
| 68 | Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). <i>Vaccine</i> , 2011, 29, 984-993. | 3.8 | 40 |
| 69 | Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. <i>Annals of Oncology</i> , 2015, 26, 2367-2374. | 1.2 | 40 |
| 70 | Dysregulated Hematopoiesis Caused by Mammary Cancer Is Associated with Epigenetic Changes and <i>Hox</i> Gene Expression in Hematopoietic Cells. <i>Cancer Research</i> , 2013, 73, 5892-5904. | 0.9 | 39 |
| 71 | Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019, 125, 1963-1972. | 4.1 | 39 |
| 72 | CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1538-1552. | 7.0 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Ovarian Cancer Early Detection Claims Are Biased. <i>Clinical Cancer Research</i> , 2008, 14, 7574.1-7574. | 7.0 | 37 |
| 74 | Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. <i>PLoS ONE</i> , 2008, 3, e3409. | 2.5 | 37 |
| 75 | PD-L1 and intratumoral immune response in breast cancer. <i>Oncotarget</i> , 2017, 8, 51641-51651. | 1.8 | 37 |
| 76 | Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. , 2019, 7, 13. | | 37 |
| 77 | A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer. <i>Oncolmmunology</i> , 2018, 7, e1371895. | 4.6 | 35 |
| 78 | Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 339-348. | 28.4 | 35 |
| 79 | Application of Bayesian Modeling of Autologous Antibody Responses against Ovarian Tumor-Associated Antigens to Cancer Detection. <i>Cancer Research</i> , 2006, 66, 1792-1798. | 0.9 | 34 |
| 80 | Uncoupling of Promitogenic and Antiapoptotic Functions of IL-2 by Smad-Dependent TGF- β 2 Signaling. <i>Journal of Immunology</i> , 2003, 170, 5563-5570. | 0.8 | 33 |
| 81 | New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. <i>Current Opinion in Immunology</i> , 2015, 33, 93-100. | 5.5 | 33 |
| 82 | Role of Interleukin (IL)-2 Receptor β -Chain Subdomains and Shc in p38 Mitogen-activated Protein (MAP) Kinase and p54 MAP Kinase (Stress-activated Protein Kinase/c-Jun N-terminal Kinase) Activation. <i>Journal of Biological Chemistry</i> , 1999, 274, 7591-7597. | 3.4 | 32 |
| 83 | CD25 Identifies a Subset of CD4+FoxP3 $^+$ TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 245-253. | 3.4 | 32 |
| 84 | Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells. <i>Cancer Research</i> , 2007, 67, 6442-6450. | 0.9 | 30 |
| 85 | Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 587-600. | 2.5 | 30 |
| 86 | MAGE-F1, a novel ubiquitously expressed member of the MAGE superfamily. <i>Gene</i> , 2001, 267, 173-182. | 2.2 | 27 |
| 87 | Polyfunctional T-Cell Responses Are Disrupted by the Ovarian Cancer Ascites Environment and Only Partially Restored by Clinically Relevant Cytokines. <i>PLoS ONE</i> , 2010, 5, e15625. | 2.5 | 27 |
| 88 | Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2226-2236. | 7.0 | 26 |
| 89 | Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 7.1 | 26 |
| 90 | Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. <i>Oncolmmunology</i> , 2017, 6, e1321184. | 4.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Loss of Parkinson's susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis. <i>Scientific Reports</i> , 2021, 11, 2097. | 3.3 | 22 |
| 92 | Expression of Chimeric Granulocyte-Macrophage Colony-Stimulating Factor/Interleukin 2 Receptors in Human Cytotoxic T Lymphocyte Clones Results in Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Growth. <i>Human Gene Therapy</i> , 1999, 10, 1941-1951. | 2.7 | 21 |
| 93 | The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. <i>Gynecologic Oncology</i> , 2020, 158, 167-177. | 1.4 | 20 |
| 94 | Proliferation and Differentiation of CD8+ T Cells in the Absence of IL-2/15 Receptor β -Chain Expression or STAT5 Activation. <i>Journal of Immunology</i> , 2004, 173, 3131-3139. | 0.8 | 19 |
| 95 | CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15-Dependent Mechanism. <i>Clinical Cancer Research</i> , 2007, 13, 7172-7180. | 7.0 | 19 |
| 96 | Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3828. | 3.7 | 19 |
| 97 | Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury. <i>Npj Precision Oncology</i> , 2021, 5, 103. | 5.4 | 18 |
| 98 | An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. <i>Journal of Immunological Methods</i> , 2010, 360, 149-156. | 1.4 | 15 |
| 99 | Validated biomarker assays confirm that <i>ARID1A</i> loss is confounded with <i>MMR</i> deficiency, <i>CD8</i> ⁺ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401. | 4.5 | 15 |
| 100 | The Apoptosis-inducing Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Analog E21R Functions through Specific Regions of the Heterodimeric GM-CSF Receptor and Requires Interleukin-1 β -converting Enzyme-like Proteases. <i>Journal of Biological Chemistry</i> , 1997, 272, 9877-9883. | 3.4 | 14 |
| 101 | The more tumors change, the more they stay tame: Do T cells keep POLE ultramutated endometrial carcinomas in check?. <i>Gynecologic Oncology</i> , 2015, 138, 1-2. | 1.4 | 14 |
| 102 | Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. <i>Communications Biology</i> , 2021, 4, 859. | 4.4 | 13 |
| 103 | Homodimerization of IL-2 receptor β chain is necessary and sufficient to activate Jak2 and downstream signaling pathways. <i>FEBS Letters</i> , 1998, 421, 32-36. | 2.8 | 12 |
| 104 | IDO and outcomes in ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 115, 179-180. | 1.4 | 12 |
| 105 | Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 8.2 | 12 |
| 106 | Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapy. <i>Oncolmmunology</i> , 2014, 3, e29243. | 4.6 | 10 |
| 107 | Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 520-529. | 1.4 | 10 |
| 108 | Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1865-1875. | 4.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 753-763. | 2.5 | 9 |
| 110 | Avelumab in newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab118. | 0.7 | 8 |
| 111 | Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model. <i>International Journal of Cancer</i> , 2009, 125, 2871-2878. | 5.1 | 7 |
| 112 | MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1259-1273. | 4.2 | 5 |
| 113 | Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis. <i>Melanoma Research</i> , 0, Publish Ahead of Print, . | 1.2 | 4 |
| 114 | Uncoupling IL-2 Signals that Regulate T Cell Proliferation, Survival, and Fas-Mediated Activation-Induced Cell Death. <i>Immunity</i> , 2009, 30, 611. | 14.3 | 3 |
| 115 | IgA transcytosis: A new weapon in the immune response to cancer?. <i>Cancer Cell</i> , 2021, 39, 607-609. | 16.8 | 2 |
| 116 | High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 443-452. | 2.5 | 2 |
| 117 | Interleukin 2 Receptor. , 1998, , 1439-1442. | | 1 |
| 118 | Personalized Immunotherapy Targeting the Cancer Mutanome. , 2016, , 426-433. | | 1 |
| 119 | Breaching B cell tolerance in the tumor microenvironment. <i>Cancer Cell</i> , 2022, 40, 356-358. | 16.8 | 1 |
| 120 | The Multifaceted Roles of B Cells and Plasma Cells in Antitumor Immunity. , 0, , . | | 1 |
| 121 | Killer T cells to the rescue in ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 124, 178-179. | 1.4 | 0 |
| 122 | The MOCOG study: Learning from extraordinary responders to improve treatment outcomes for women with ovarian cancer. <i>Pathology</i> , 2020, 52, S30-S31. | 0.6 | 0 |
| 123 | Genetic Modification of T Cell Clones to Improve the Safety and Efficacy of Adoptive T Cell Therapy. <i>Novartis Foundation Symposium</i> , 1994, 187, 212-228. | 1.1 | 0 |
| 124 | Effects of Standard Treatments on the Immune Response to Prostate Cancer. , 2008, , 531-555. | | 0 |
| 125 | Single Cell Profiling Reveals Unique CXCL13 Positive T Cell Subsets in the Tumor Microenvironment of Lymphocyte Rich Classic Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 32-33. | 1.4 | 0 |